



**Coventry and  
Warwickshire**  
Integrated Care Board

# Commissioning Policy

Reference Number:	This will be applied to all new ICB-wide PPSs by the Governance and Corporate Affairs Team and will be retained throughout its life span.
Version:	Version 1.0
Name of responsible Committee and date approved or recommended to Integrated Care Board Board:	Audit Committee
Date approved by the Integrated Care Board (if applicable):	1 July 2022
Next Review Date:	1 April 2024
Expiry Date:	1 July 2024
Name of author and title:	
Name of reviewer and title:	
Department:	Corporate Office

#### VERSION HISTORY

Date	Version	Changes made to previous version	Consulting and Endorsing Stakeholders, Committees / Meetings / Forums etc.

<b>Treatment</b>	Dupuytren's Disease surgery
<b>Indication</b>	Dupuytren's Disease
<b>Treatment:</b>	<p>Treatment is not indicated in cases where there is no contracture, and in patients with a mild (less than 20°) contractures, or one which is not progressing and does not impair function.</p> <p>An intervention (collagenase injections*, needle fasciotomy, fasciectomy and dermofasciectomy) should be considered for:</p> <p>A. Finger contractures causing loss of finger extension of 30° or more at the metacarpophalangeal joint or 20° at the proximal interphalangeal joint; <b>OR</b></p> <p>B. Severe thumb contractures which interfere with function.</p> <p>NICE concluded that collagenase should <b>ONLY</b> be used for:</p> <p>A. Participants in the ongoing clinical trial (HTA-15/102/04); <b>OR</b></p> <p>B. Adult patients with a palpable cord if:</p> <ul style="list-style-type: none"> <li>• There is evidence of moderate disease (functional problems and metacarpophalangeal joint contracture of 30° to 60° and proximal interphalangeal joint contracture of less than 30° or first web contracture), plus up to two affected joints; <b>AND</b></li> <li>• Needle fasciotomy is not considered appropriate, but limited fasciectomy is considered appropriate by the treating hand surgeon</li> </ul> <p>* <b>Collagenase Clostridium Histolyticum (Xiapex®)</b> The ICB approves the prescribing of Collagenase Clostridium Histolyticum injection (Xiapex®), by HAND SURGEONS only, in an outpatient setting, for the treatment of Dupuytren's contracture with a palpable cord in adults in accordance with NICE TA459. NICE TA459 (26 July 2017) recommends that people who meet the inclusion criteria for the ongoing clinical trial (HTA 15/102/04), comparing Collagenase Clostridium Histolyticum (CCH) to limited fasciectomy, are encouraged to participate in the study.</p> <p>Prior approval from the Integrated Care Board will be required before any treatment proceeds in secondary care unless an alternative contract arrangement has been agreed with the ICB that does not necessitate the requirement of prior approval before treatment.</p>
<b>Equality Impact</b>	<a href="https://www.england.nhs.uk/publication/evidence-based-interventions-policy-equality-and-health-inequalities-full-analysis-form/">https://www.england.nhs.uk/publication/evidence-based-interventions-policy-equality-and-health-inequalities-full-analysis-form/</a>